ACT-462206;(2S)-N-(3,5-DIMETHYLPHENYL)-1-(4-METHOXYPHENYL)SULFONYLPYRROLIDINE-2-CARBOXAMIDE;(2S)-N-(3,5-Dimethylphenyl)-1-[(4-methoxyphenyl)sulfonyl]-2-pyrrolidinecarboxamide;ACT-462206 >=98% (HPLC);ACT 462206,ACT462206;2-Pyrrolidinecarboxamide, N-(3,5-dimethylphenyl)-1-[(4-methoxyphenyl)sulfonyl]-, (2S)-;ACT-462206, 10 mM in DMSO
ACT-462206 is a potent and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors. It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in some animal models while showing anxiolytic-like properties without affecting cognition and motor function in others.
